NAFLD Among Patients With Type 2 Diabetes and CKD
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03826381|
Recruitment Status : Recruiting
First Posted : February 1, 2019
Last Update Posted : May 30, 2019
|First Submitted Date||March 18, 2018|
|First Posted Date||February 1, 2019|
|Last Update Posted Date||May 30, 2019|
|Actual Study Start Date||May 6, 2019|
|Estimated Primary Completion Date||August 2021 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures
||Prevalence of NAFLD and actual estimate of liver signal measured by MR spectroscopy [ Time Frame: 1 day ]
Liver signal is measured by MR spectroscopy
|Original Primary Outcome Measures||Same as current|
|Current Secondary Outcome Measures
|Original Secondary Outcome Measures||Same as current|
|Current Other Pre-specified Outcome Measures||Not Provided|
|Original Other Pre-specified Outcome Measures||Not Provided|
|Brief Title||NAFLD Among Patients With Type 2 Diabetes and CKD|
|Official Title||Prevalence and Metabolic Impact of Non-alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes With Normal Renal Function or Chronic Kidney Disease|
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developed countries affecting approximately 30 % of the general adult population. It represents an important pathogenic factor in the development of type 2-diabetes and is associated with a high risk of cardiovascular disease. Previous studies of patients with chronic kidney disease (CKD) have demonstrated an increased risk for NAFLD and the presence of both CKD and NAFLD is likely to increase the risk for cardiovascular disease.
The present protocol describes a study of the prevalence and etiology of NAFLD among patients with type 2-diabetes with CKD.
The study is a cross-sectional study. Fat accumulation in the liver will be determined by Magnetic resonance (MR) spectroscopy and the prevalence of NAFLD among patients with type 2-diabetes with normal kidney function or CKD stage 3-5 will be investigated. A continuous glucose monitoring (CGM) for four days, Dual Energy X-ray Absorptiometry (DEXA) scanning, fibro scanning of the liver, bile acid analysis, metabolomic and lipidomic analysis will also be performed.
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developed countries affecting approximately 30 % of the general adult population. The disease is defined by an increased fat accumulation in the liver cells (>5 %), not caused by excessive alcohol intake (a threshold of 20 g per day for women and 30 g per day for men), autoimmunity, drugs or viral hepatitis. The histological spectrum of NAFLD ranges from simple steatosis to non-alcoholic steatohepatitis (NASH). Simple steatosis defined as steatosis without injury of the hepatocytes in form of ballooning and NASH defined as the presence of hepatic steatosis and inflammation with ballooned hepatocytes with or without fibrosis. The degree of fibrosis is an important prognostic factor and is related to liver related complications and mortality.
Diabetes is the single most important cause of end-stage renal disease (ESRD). Furthermore, more than 25 % of patients with moderate to severe chronic kidney disease (CKD) have pre-diabetic characteristics such as impaired glucose tolerance or impaired fasting glucose. NAFLD represents an important pathogenic factor in the development of type 2-diabetes and is associated with an increased risk of cardiovascular disease, insulin resistance and overweight.
Previous studies of patients with CKD with/without diabetes demonstrated, with less sensitive ultrasonic methods than what we plan to use in the present project, a high prevalence of NAFLD. Furthermore, the presence of both NAFLD and CKD is likely to increase the risk for cardiovascular diseases and mortality, particular among overweight patients. NAFLD is present in both diabetic and nondiabetic patients with ESRD. The co-existence of CKD, NAFLD and gluco-metabolic disturbances, including diabetes, is a research topic with increasing focus on. Co-morbidities in CKD such as impaired insulin sensitivity, diabetes, impaired calcium-phosphate metabolism, hypertension and hypertriglyceridemia constitute risk factors for NAFLD. Unfortunately, several treatments of CKD, including kidney transplantation, have been shown to impair lipid metabolism and increase insulin resistance especially in the liver. Importantly, lifestyle changes and medical treatment modalities have been shown to have only minor impact on reducing the prevalence of these disturbances in patients with CKD.
In patients with NAFLD, either due to metabolic stress (obesity) or toxic substances (immunosuppressive treatment), liver damage and the impact on insulin resistance is reflected in characteristic modifications of metabolites and lipids in liver tissue, as well as in circulating blood, which may help to identify and interpret the pathogenesis of liver damage in the setting of CKD. One recent hypothesis for linking liver damage and CKD involves a change in gut microbiota due to impaired renal function, leading to a leaky gut with damage of the gut-blood barrier. This transfers gut microbiota metabolites to the blood, leading to a pathogen-associated molecular pattern, reflected in changes in lipidomic and metabolomic profile in the blood. Such changes have in other conditions been associated with insulin resistance and have been linked to liver damage leading to NAFLD and later potentially fibrosis.
Very little information about bile acid metabolism in the development of NAFLD in CKD patients with type 2-diabetes is available. Risk factors for NAFLD among patients with CKD have only been investigated in small-scale studies with often inadequate methods. No studies have investigated the impact of fat lipid content measured by MR spectroscopy in patients with type 2-diabetes and CKD stage 3-5. New therapeutic strategies for the diagnosis and management of NAFLD in patients with CKD with diabetes are needed and important challenges in the elucidation of the ethology, pathogenesis and prevalence of NAFLD in CKD patients exist.Thus, this project will bring new knowledge among a group of patients with high morbidity and an increased risk of mortality - a knowledge that may provide new guidelines for prevention and treatment of NAFLD.
The primary objective of this project is to study the association between the kidney function and the prevalence of NAFLD and the association with type 2-diabetes.
Furthermore, secondary objectives are to investigate potential associations between NAFLD in type 2-diabetes CKD patients and glucose profiles, metabolomics- and lipidomics profiles, intestinal peptides and the bile acid metabolism.
Study design and population
This is a cross-sectional cohort study involving 54 patients with type 2-diabetes with normal kidney function and 54 patients with type 2-diabetes and CKD stage 3-5 (not on dialysis).
The patients will be recruited from the outdoor clinic of either endocrinology or nephrology at Rigshospitalet, Herlev Hospital, Steno Diabetes Center Copenhagen and Gentofte Hospital.
The project involves following methods.
Magnetic resonance (MR) spectroscopy Fibroscan and clinical index Blood samples Dual Energy X-ray Absorptiometry scan Continuous Glucose Monitoring Clinical examination
Data and statistical analysis
The null hypothesis is that there is no difference in relative liver lipid signal measured by MR spectroscopy between type 2-diabetic patients with CKD stage 3-5 and patients with type 2-diabetes and normal renal function.
The alternative hypothesis is that there is a difference of 30% in liver lipid signal between type 2-diabetic patients with CKD stage 3-5 and patients with type 2-diabetes and normal renal function. In the literature content in relative liver fat signal in patients with type 2-diabetes and CKD 3-5 is about 60% and in type 2-diabetes patients with normal function it is about 30%. In a two-sided t-test with α=0.05 and power of 80%, a sample size of 98 patients in a parallel design is needed to demonstrate a difference in relative liver fat signal between type 2-diabetes patients with CKD 3 and 5 and type 2 diabetes patients with normal renal function of 30%. A total of 108 patients, including 10 extra patients, are planned to be examined.
After completion of the study and data completion the results are analysed according to primary and secondary endpoints. Results are reported as mean values with confidence interval or median and range. Data are analysed with parametric (normally distributed data) or non-parametric statistics (non-normal distributed data). A 95 % confidence interval is accepted as statistically significant (p < 0.05).
All data will be pseudo anonymised.
|Study Design||Observational Model: Cohort
Time Perspective: Cross-Sectional
|Target Follow-Up Duration||Not Provided|
|Biospecimen||Retention: Samples Without DNA
Blood samples will be collected for both immediately analyses (basic lab data) and later analyses (bile acids,lipidomics and metabolomics) and stored for 10 years whereafter they will be destroyed.
|Sampling Method||Non-Probability Sample|
Total number of participants: 108 divided in two Groups:
The patients are recruited from the department of Endocrinology or Nephrology at Rigshospitalet (if necessary, from Herlev Hospital, Gentofte Hospital or Steno Diabetes Center Copenhagen also).
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Original Estimated Enrollment||Same as current|
|Estimated Study Completion Date||December 2021|
|Estimated Primary Completion Date||August 2021 (Final data collection date for primary outcome measure)|
|Ages||18 Years to 90 Years (Adult, Older Adult)|
|Accepts Healthy Volunteers||Yes|
|Listed Location Countries||Denmark|
|Removed Location Countries|
|Other Study ID Numbers||NAFLD and CKD - Study 1|
|Has Data Monitoring Committee||Yes|
|U.S. FDA-regulated Product||
|IPD Sharing Statement||
|Responsible Party||Bo Feldt-Rasmussen, Rigshospitalet, Denmark|
|Study Sponsor||Rigshospitalet, Denmark|
|PRS Account||Rigshospitalet, Denmark|
|Verification Date||May 2019|